JP Morgan Chase’s Aerie Pharmaceuticals AERI Stock Holding History

JP Morgan Chase’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-40,000	Closed	-$2.46M	–	6025
2018 Q3	$2.46M	Sell	40,000 -230,000	-85%	-$14.8M	﹤0.01%	3310
2018 Q2	$18.2M	Buy	+270,000	New	+$15.1M	﹤0.01%	1663
2017 Q4	–	Sell	-13,500	Closed	-$664K	–	5637
2017 Q3	$664K	Buy	+13,500	New	+$737K	﹤0.01%	3708

JP Morgan Chase's AERI Position: Q4 2022 in Review

JP Morgan Chase sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 562,108 shares — an estimated $8.5M sold.

JP Morgan Chase first reported a position in AERI in Q3 2014 and held it in 25 quarters. The position peaked at $8.5M in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

JP Morgan Chase reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
JP Morgan Chase sold 562,108 Aerie Pharmaceuticals shares in Q4 2022, an estimated $8.5M.
JP Morgan Chase first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 25 quarters.
JP Morgan Chase's Aerie Pharmaceuticals position peaked at $8.5M in Q3 2022.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.